Nexcella Inc.
Clinical trials sponsored by Nexcella Inc., explained in plain language.
Now part of
Immix Biopharma, Inc.
IMMX
NASDAQ
Biotech developing cell therapies for solid tumors.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take aim at a rare Protein-Clogging disease Results expected Dec 2026 (estimated) May already have reported ↗